Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib Phase 2 Dose-Finding Study in Japanese Patients
NCT05421078Phase 2Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of obicetrapib in dyslipidemia and hypercholesterolemia (4 arms), sponsored by NewAmsterdam Pharma. Primary endpoints: Mean/Median/LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (Friedewald) at 8 weeks and Mean/Median/LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (PUC) at 8 weeks. Started Jun 2022; status: completed.
02
Drugs
obicetrapib
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on NCT05421078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05421078.